Fig. 1 · Structure

Documents & Downloads

Idelalisib (CAL-101, GS-1101)

Cat. No. A10172 CAS 870281-82-6

PI3K inhibitor

CAL-101 is an isoform-selective inhibitor of PI3K that induces apoptosis of chronic lymphocytic leukemia (CLL) cells.

In Stock

Publications for Idelalisib

5 publications citing this product

  1. Kevin J Pridham, .et al. , iScience, 2024, May 7;27(6):109921 PMID: 38812542
  2. Ming-Chun Hung, .et al. , Cell Biosci, 2022, 12: 122 PMID: 35918763
  3. Hirosumi Tamura, .et al. , Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168
  4. Pridham KJ, .et al. , Neuro Oncol, 2018, Mar 27;20(4):494-505 PMID: 29016844
  5. Yoshihiro Umezawa, .et al. , J Biol Chem, 2017, Dec 1; 292(48): 19639-19655 PMID: 28974577

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

CAL-101 inhibits recombinant PI3K p110δ with a reported IC50 of 2.5 nM, compared with 89–820 nM for the other class I isoforms in the same assay panel. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
p110δ IC50 2.5nM
p110γ IC50 89nM
p110β IC50 565nM
p110α IC50 820nM
hVps34 IC50 978nM
C2β IC50 >1μM
mTOR IC50 >1μM
PIP5Kα IC50 >1μM
PIP5Kβ IC50 >1μM
DNA-PK IC50 6.729μM

10 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
A498 GI50 1.1 μM Antiproliferative activity against human A498 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay [PMID: 32212730]
A549 IC50 0.33 μM Antiproliferative activity against human A549 cells after 72 hrs by MTT assay 10.1039/C5MD00364D
B-cell IC50 0.0061 μM Inhibition of PI3Kdelta in B-cells by proliferation assay [PMID: 22924688]
Bel-7402 IC50 66.23 μM Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay [PMID: 35191698]
CAKI-1 GI50 20.5 μM Antiproliferative activity against human Caki1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay [PMID: 32212730]
CCRF-CEM GI50 22.3 μM Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition measured after 48 hrs by SRB assay [PMID: 32212730]
DOHH-2 IC50 0.86 μM Cytotoxicity against human DOHH-2 cells expressing BTK and PI3kdelta assessed as inhibition of cell growth incubated for 72 hrs by celltiter-glo assay [PMID: 35247756]
HCC 2998 GI50 38.5 μM Antiproliferative activity against human HCC2998 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay [PMID: 32212730]
HCT-116 IC50 > 10 μM Antiproliferative activity against human HCT116 cells by MTT assay [PMID: 31434616]
HCT-116 IC50 2.96 μM Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CCK-8 assay [PMID: 36182802]
HEK293 IC50 > 20 μM Cytotoxicity against human HEK293 cells assessed as reduction in cell viability by MTS assay [PMID: 32784091]
HeLa IC50 0.15 μM Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay 10.1039/C5MD00364D
Hep 3B2 IC50 77.55 μM Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay [PMID: 35191698]
HepG2 IC50 0.92 μM Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay 10.1039/C5MD00364D
HepG2 IC50 89.5 μM Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay [PMID: 35191698]
HOP-62 GI50 > 100 μM Antiproliferative activity against human HOP62 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay [PMID: 32212730]
HOP-92 GI50 14.1 μM Antiproliferative activity against human HOP92 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay [PMID: 32212730]
Hs-578T GI50 6 μM Antiproliferative activity against human Hs578T cells assessed as cell growth inhibition measured after 48 hrs by SRB assay [PMID: 32212730]
HT IC50 > 10 μM Antiproliferative activity against human HT cells measured after 72 hrs by alamar blue assay [PMID: 27846451]
HUVEC IC50 38.22 μM Cytotoxicity against HUVEC cells incubated for 72 hrs by CCK-8 assay [PMID: 36182802]

20 records · Scroll to view more

Idelalisib (CAL-101, GS-1101) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Idelalisib (CAL-101, GS-1101) from 3 published references. In vitro models include recombinant class I PI3Ks.

Idelalisib (CAL-101, GS-1101) In Vitro Studies

Primary leukemia samples showed heterogeneous sensitivity to CAL-101: viability EC50 values below 1 μM occurred in 5/22 B-ALL and 11/42 CLL samples, versus 1/31 AML and 0/39 MPN samples. Five normal PBMC samples showed no sensitivity in this screen. [1]

At 5 μM, CAL-101 reduced CXCL12- and CXCL13-directed migration of primary CLL cells in a Transwell assay (10 patients). This migration endpoint complements the viability evidence. [2]

Recombinant PI3K isoform inhibition

Biochemical assay · Recombinant class I PI3Ks [1]

CAL-101 inhibited p110δ more potently than the other class I isoforms.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Recombinant class I PI3K inhibitionIC50 p110δ: 2.5 nM; p110α: 820 nM; p110β: 565 nM; p110γ: 89 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
5.0–10^4 nM
Method
In vitro enzyme inhibition profiling
Vehicle
DMSO stock, 10 mM
Reported limits
Reaction duration and replicate counts are not given in the read main caption; linked SI not acquired.
Methods and source locations

Compound reported in the paper: CAL-101 (idelalisib); Compound label in the paper: CAL-101

Named-compound evidence; tested material does not establish purity, potency or performance of an Adooq lot.

Figure 1A-B and caption; Methods: In vitro kinase profiling; selectivity Results

Recombinant class I PI3K inhibition: 10-point enzyme inhibitory activity profiling; ATP at each enzyme’s Km. — Figure 1B (viewed table); caption

Heterogeneous sensitivity of primary leukemia samples

Cell-based study · Primary B-ALL (n=22), CLL (n=42), AML (n=31), MPN (n=39); normal PBMC samples (n=5) [1]

Only subsets of B-ALL and CLL samples met the authors’ sensitivity threshold; most samples did not.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Samples with viability EC50 <1 μMSample counts B-ALL: 5/22 (23%); CLL: 11/42 (26%); AML: 1/31 (3%); MPN: 0/39 (0%)[1]
Normal peripheral blood mononuclear cell sensitivityQualitative No sensitivity observed in 5 control samples[1]

Literature-Reported Treatment Conditions

Treatment concentration
Maximum tested: 10 μM
Method
Ex vivo viability concentration-response screen
Reported limits
Exposure duration and final vehicle fraction are not specified in the read main text; SI not acquired. No duration inferred from neighboring apoptosis experiments.
Methods and source locations

Compound reported in the paper: CAL-101 (idelalisib); Compound label in the paper: CAL-101

Named-compound evidence; tested material does not establish purity, potency or performance of an Adooq lot.

Figure 2A and caption; primary-cell sensitivity Results; main Methods

Samples with viability EC50 <1 μM: Tetrazolium-based viability assay; sensitivity relative to untreated cells; maximum tested concentration 10 μM. — Sensitivity of primary cells Results; Figure 2A caption

Normal peripheral blood mononuclear cell sensitivity: Same primary-cell screen; no numerical normal-cell EC50 assigned. — Primary-cell sensitivity Results; Figure 2A

Reduced chemokine-directed migration of primary CLL cells

Cell-based study · Primary CLL cells from 10 patients; Transwell migration toward CXCL12 or CXCL13 [2]

CAL-101 reduced migration toward both chemokines relative to no-drug controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cells migrating toward CXCL12Mean ± SEM migrated cells Control: 7022 ± 1420; CAL-101: 4044 ± 918; P < .05; n=10 patients[2]
Cells migrating toward CXCL13Mean ± SEM migrated cells Control: 6179 ± 1742; CAL-101: 2276 ± 470; P < .05; n=10 patients[2]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM
Exposure duration
1-hour pretreatment; 3-hour migration assay
Method
Methods describe anti-IgM (10 μg/mL) during pretreatment, with or without CAL-101; chemokine-free control also included.
Vehicle
DMSO stock, 10 mM; final fraction not specified
Reported limits
Figure 1A caption omits anti-IgM, which is explicitly included in the Chemotaxis assay Methods. Final vehicle-matching details not stated there.
Methods and source locations

Compound reported in the paper: CAL-101 (idelalisib); Compound label in the paper: CAL-101

Named-compound evidence; tested material does not establish purity, potency or performance of an Adooq lot.

Methods: Chemotaxis assay and data analysis; first Results subsection; Figure 1A and caption

Cells migrating toward CXCL12: Transwell assay with 200 ng/mL CXCL12; flow-cytometric counting. — First Results subsection; Figure 1A

Cells migrating toward CXCL13: Transwell assay with 1 μg/mL CXCL13; flow-cytometric counting. — First Results subsection; Figure 1A

Idelalisib (CAL-101, GS-1101) In Vivo Studies

In a panel of B-ALL patient-derived xenografts, oral idelalisib at 50 mg/kg daily for 2–4 weeks produced a mean 38.1% reduction in splenic leukemia counts versus vehicle (range 13.9%–53.1% across models). Responses were partial and weaker than with gedatolisib; the authors noted possible mouse solubility and pharmacokinetic limitations. [3]

Partial leukemia suppression in B-ALL xenografts

Animal study · NSG mice bearing patient-derived B-ALL; 10 genetically varied models [3]

Daily idelalisib partially reduced leukemia burden; the dual PI3K/mTOR inhibitor gedatolisib was more effective.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Reduction of splenic human leukemia cell count versus vehicleMean and range across PDX models 38.1% (range, 13.9%–53.1%)[3]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Daily
Treatment course
2–4 weeks, depending on progression in vehicle controls; planned maximum 28 days
Vehicle
0.5% hydroxypropyl methylcellulose / 0.2% Tween 80 in water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Idelalisib monotherapy
50 mg/kg per dose
Corresponding vehicle-treated miceMean reduction in splenic leukemia cell counts versus vehicle: 38.1% (range 13.9%–53.1% across models). Partial responses; stronger suppression with gedatolisib.[3]
Idelalisib monotherapy
Model: NSG mouse B-ALL patient-derived xenografts across 10 models (9 Ph-like, 1 non–Ph-like); 5 mice per treatment arm per model
Reported limits: Age and sex not specified in the read efficacy methods. This selected arm has no survival-benefit claim.
Methods and source locations

Compound reported in the paper: CAL-101 (idelalisib); Compound label in the paper: idelalisib

Named-compound evidence; tested material does not establish purity, potency or performance of an Adooq lot.

Figure 1A-D and caption; Table 1; efficacy Results; xenograft/efficacy/statistical Methods; Discussion

Reduction of splenic human leukemia cell count versus vehicle: Human-marker flow cytometry with absolute counting beads; 5 mice per treatment arm per model. Mean/range describe model responses, not SEM or individual-mouse dispersion. — First efficacy Results subsection; Figure 1

Idelalisib monotherapy · Figure 1A-D; efficacy Results; In vivo therapeutic efficacy studies; Table 1

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 870281-82-6
Applications PI3K inhibitor
Formula C22H18FN7O
Molecular Weight 415.4
Synonyms CAL-101; GS-1101
SMILES
CC[C@@H](C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 76 mg/mL (182.94 mM)
Water Insoluble
Ethanol 21 mg/mL (50.55 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
2% DMSO+20%PEG 300+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Idelalisib (CAL-101, GS-1101) Research References

  1. [1] Brian J Lannutti, Sarah A Meadows, Sarah E M Herman, et al. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Blood (2011). PMID: 20959606 DOI: 10.1182/blood-2010-03-275305 Source material
  2. [2] Julia Hoellenriegel, Sarah A Meadows, Mariela Sivina, et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia Blood (2011). PMID: 21803855 DOI: 10.1182/blood-2011-05-352492 Source material
  3. [3] Sarah K Tasian, David T Teachey, Yong Li, et al. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia Blood (2017). PMID: 27777238 DOI: 10.1182/blood-2016-05-707653 Source material

Publications

5 publications citing this product

  1. Kevin J Pridham, .et al. , iScience, 2024, May 7;27(6):109921 PMID: 38812542
  2. Ming-Chun Hung, .et al. , Cell Biosci, 2022, 12: 122 PMID: 35918763
  3. Hirosumi Tamura, .et al. , Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168
  4. Pridham KJ, .et al. , Neuro Oncol, 2018, Mar 27;20(4):494-505 PMID: 29016844
  5. Yoshihiro Umezawa, .et al. , J Biol Chem, 2017, Dec 1; 292(48): 19639-19655 PMID: 28974577

Added to your cart

View Cart Checkout
Loading...